QQQ   308.74 (+2.60%)
AAPL   149.32 (+2.67%)
MSFT   259.60 (+2.71%)
META   182.47 (+19.17%)
GOOGL   106.67 (+6.21%)
AMZN   110.30 (+4.90%)
TSLA   189.64 (+4.54%)
NVDA   213.83 (+2.10%)
NIO   12.15 (+0.41%)
BABA   110.01 (-2.49%)
AMD   85.76 (+1.32%)
T   20.14 (-0.20%)
MU   62.95 (+0.56%)
F   14.20 (+2.97%)
CGC   3.15 (+2.27%)
GE   82.42 (+0.12%)
DIS   110.25 (+0.79%)
AMC   6.16 (+7.88%)
PFE   43.74 (-0.52%)
PYPL   86.98 (+4.91%)
NFLX   361.08 (-0.25%)
QQQ   308.74 (+2.60%)
AAPL   149.32 (+2.67%)
MSFT   259.60 (+2.71%)
META   182.47 (+19.17%)
GOOGL   106.67 (+6.21%)
AMZN   110.30 (+4.90%)
TSLA   189.64 (+4.54%)
NVDA   213.83 (+2.10%)
NIO   12.15 (+0.41%)
BABA   110.01 (-2.49%)
AMD   85.76 (+1.32%)
T   20.14 (-0.20%)
MU   62.95 (+0.56%)
F   14.20 (+2.97%)
CGC   3.15 (+2.27%)
GE   82.42 (+0.12%)
DIS   110.25 (+0.79%)
AMC   6.16 (+7.88%)
PFE   43.74 (-0.52%)
PYPL   86.98 (+4.91%)
NFLX   361.08 (-0.25%)
QQQ   308.74 (+2.60%)
AAPL   149.32 (+2.67%)
MSFT   259.60 (+2.71%)
META   182.47 (+19.17%)
GOOGL   106.67 (+6.21%)
AMZN   110.30 (+4.90%)
TSLA   189.64 (+4.54%)
NVDA   213.83 (+2.10%)
NIO   12.15 (+0.41%)
BABA   110.01 (-2.49%)
AMD   85.76 (+1.32%)
T   20.14 (-0.20%)
MU   62.95 (+0.56%)
F   14.20 (+2.97%)
CGC   3.15 (+2.27%)
GE   82.42 (+0.12%)
DIS   110.25 (+0.79%)
AMC   6.16 (+7.88%)
PFE   43.74 (-0.52%)
PYPL   86.98 (+4.91%)
NFLX   361.08 (-0.25%)
QQQ   308.74 (+2.60%)
AAPL   149.32 (+2.67%)
MSFT   259.60 (+2.71%)
META   182.47 (+19.17%)
GOOGL   106.67 (+6.21%)
AMZN   110.30 (+4.90%)
TSLA   189.64 (+4.54%)
NVDA   213.83 (+2.10%)
NIO   12.15 (+0.41%)
BABA   110.01 (-2.49%)
AMD   85.76 (+1.32%)
T   20.14 (-0.20%)
MU   62.95 (+0.56%)
F   14.20 (+2.97%)
CGC   3.15 (+2.27%)
GE   82.42 (+0.12%)
DIS   110.25 (+0.79%)
AMC   6.16 (+7.88%)
PFE   43.74 (-0.52%)
PYPL   86.98 (+4.91%)
NFLX   361.08 (-0.25%)
NASDAQ:KPTI

Karyopharm Therapeutics - KPTI Stock Forecast, Price & News

$3.37
+0.03 (+0.90%)
(As of 02/2/2023 10:04 AM ET)
Add
Compare
Today's Range
$3.35
▼
$3.41
50-Day Range
$2.48
▼
$5.29
52-Week Range
$2.45
▼
$14.73
Volume
102,722 shs
Average Volume
3.11 million shs
Market Capitalization
$273.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.33

Karyopharm Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
179.4% Upside
$9.33 Price Target
Short Interest
Bearish
26.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.38mentions of Karyopharm Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$46,726 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.93) to ($1.33) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

135th out of 1,053 stocks

Pharmaceutical Preparations Industry

55th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

KPTI stock logo

About Karyopharm Therapeutics (NASDAQ:KPTI) Stock

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Stock News Headlines

January 30, 2023 | americanbankingnews.com
Karyopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $5.00
January 30, 2023 | americanbankingnews.com
Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $9.56
February 2, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
January 19, 2023 | benzinga.com
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Karyopharm Therapeutics Inc. (KPTI) Investigation
January 19, 2023 | msn.com
Karyopharm gains as Piper issues bullish remarks citing cancer drug
January 15, 2023 | seekingalpha.com
Karyopharm Therapeutics (KPTI) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow
January 9, 2023 | finance.yahoo.com
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives
January 4, 2023 | finance.yahoo.com
Karyopharm to Present at 41st Annual J.P. Morgan Healthcare Conference
February 2, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
December 28, 2022 | seekingalpha.com
Karyopharm: Recent Sell-Off Hits A New Buy Target
December 25, 2022 | seekingalpha.com
Karyopharm: 6 Months Later, No Change In My Stance
December 12, 2022 | markets.businessinsider.com
Karyopharm Announces Updated Phase 1 Data Of Selinexor Combination In Treatment-Naïve Myelofibrosis
December 12, 2022 | finance.yahoo.com
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022
December 5, 2022 | finance.yahoo.com
Karyopharm Announces $165 Million Private Placement
December 5, 2022 | finance.yahoo.com
Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis
November 21, 2022 | seekingalpha.com
Merck deal for Imago is positive for Karyopharm, Prelude – Barclays
November 8, 2022 | finance.yahoo.com
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 96% as Wall Street Analysts Expect?
November 4, 2022 | seekingalpha.com
Karyopharm Therapeutics Inc. (KPTI) Q3 2022 Earnings Call Transcript
November 3, 2022 | finance.yahoo.com
Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022
November 1, 2022 | finance.yahoo.com
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
October 20, 2022 | finance.yahoo.com
Karyopharm to Report Third Quarter 2022 Financial Results on November 3, 2022
September 23, 2022 | finance.yahoo.com
Karyopharm Therapeutics Inc. (KPTI)
September 9, 2022 | markets.businessinsider.com
Expert Ratings for Karyopharm Therapeutics
September 7, 2022 | finance.yahoo.com
Karyopharm to Participate at Upcoming Investor Conferences
August 12, 2022 | finance.yahoo.com
Why Karyopharm Therapeutics Inched Higher Today
August 5, 2022 | nasdaq.com
The past three years for Karyopharm Therapeutics (NASDAQ:KPTI) investors has not been profitable
August 4, 2022 | seekingalpha.com
Karyopharm Therapeutics, Inc. (KPTI) CEO Richard Paulson on Q2 2022 Results - Earnings Call Transcript
See More Headlines
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Company Calendar

Last Earnings
11/03/2021
Today
2/02/2023
Next Earnings (Estimated)
2/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KPTI
CUSIP
N/A
CIK
1503802
Web
www.karyopharm.com
Phone
(617) 658-0600
Fax
N/A
Employees
442
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.33
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+177.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-124,090,000.00
Net Margins
-35.26%
Pretax Margin
-35.19%
Return on Equity
N/A
Return on Assets
-32.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.61
Quick Ratio
3.54

Sales & Book Value

Annual Sales
$209.82 million
Price / Sales
1.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.05) per share
Price / Book
-3.21

Miscellaneous

Outstanding Shares
81,150,000
Free Float
72,845,000
Market Cap
$273.48 million
Optionable
Optionable
Beta
-0.04

Key Executives

  • Richard A. Paulson
    President, CEO & Non-Executive Director
  • Mike Mason
    Chief Financial Officer, Treasurer & EVP
  • Reshma Rangwala
    Chief Medical Officer & Executive Vice President
  • Accumanno James
    Chief Compliance Officer
  • Tanya N. Lewis
    Chief Regulatory & Quality Officer, Executive VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KPTI Stock - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPTI shares.
View KPTI analyst ratings or view top-rated stocks.

What is Karyopharm Therapeutics' stock price forecast for 2023?

8 Wall Street research analysts have issued 1 year target prices for Karyopharm Therapeutics' shares. Their KPTI share price forecasts range from $5.00 to $16.00. On average, they predict the company's stock price to reach $9.33 in the next twelve months. This suggests a possible upside of 179.4% from the stock's current price.
View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts.

How have KPTI shares performed in 2023?

Karyopharm Therapeutics' stock was trading at $3.40 at the start of the year. Since then, KPTI shares have decreased by 1.8% and is now trading at $3.34.
View the best growth stocks for 2023 here.

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our KPTI earnings forecast.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.01. The firm had revenue of $37.69 million for the quarter, compared to analysts' expectations of $25.84 million. During the same quarter in the previous year, the company posted ($0.73) earnings per share.

What guidance has Karyopharm Therapeutics issued on next quarter's earnings?

Karyopharm Therapeutics updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $157.70 million-$157.70 million, compared to the consensus revenue estimate of $161.68 million.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.18%), New York State Common Retirement Fund (0.06%), Redwood Wealth Management Group LLC (0.04%), Allspring Global Investments Holdings LLC (0.03%), Dupont Capital Management Corp (0.03%) and Janney Montgomery Scott LLC (0.01%). Insiders that own company stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Ran Frenkel, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Tanya Lewis.
View institutional ownership trends.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $3.34.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $271.04 million and generates $209.82 million in revenue each year. The company earns $-124,090,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

The company employs 442 workers across the globe.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com.

This page (NASDAQ:KPTI) was last updated on 2/2/2023 by MarketBeat.com Staff